

# Oxtex Ltd. is seeking £330,000 of development funding

MEDICAL

EARLY STAGE

OXFORD

EXPERIENCED MANAGEMENT TEAM



**Oxtex Ltd.** [www.oxtex.com](http://www.oxtex.com)

**Seeks to raise £330k development funding of a total round of £750k**

This opportunity may not be suitable or appropriate for your personal circumstances. The levels and basis of taxation may change and depends on your individual circumstances. The marketability of this type of investment is often restricted and you may have difficulty selling at any price. If you are in any doubt, you should consult a suitably qualified financial advisor.

## Company

Oxtex Ltd. is an early-stage medical device company which has developed a novel self-inflating tissue expander for the use in reconstructive and dental/oral surgery based on technology developed at Oxford University. A tissue expander enables the creation of additional skin through controlled stretching in a wide variety of anatomical locations. The expander has applications in many areas of plastic surgery (burns/scar revision, breast reconstruction, cleft palates, crossbite), as well as the veterinary market (tumour removal). Successful tissue expansion reduces the cost of treatment and is a significant improvement to other alternative forms of surgical reconstruction.



The global market for veterinary and medical tissue expanders is estimated today at over \$1b annually with significant growth in a number of sectors, especially in dental/oral applications.

## Management Team

The company is led by Dr David Jackson (CEO) an experienced entrepreneur with over 25 years' experience in early stage technology companies and a proven track record of taking early-stage opportunities through to successful exit. The most likely exit scenario is through a trade sale. With a successful marketed product addressing a secure global market Oxtex anticipates that applying industry standard multiples of revenue and EBITDA will result in an attractive valuation for the company.

## Investment

The company raised an initial £450k round of seed funding. It secured further investment of £300k in 2012 to continue its development as well as a grant from the Technology Strategy Board to develop a scalable manufacturing process. All investments to date have qualified for EIS relief. It has also secured a £1.25m research collaboration with the University of Malaya to develop devices for the treatment of crossbite in man. Funds raised will be used to:

- Strengthen senior management ahead of product launch
- Launch the first veterinary products in Q1 2014 starting in the UK and Europe followed by the US in 2015
- Complete the in-human UK based clinical trials for scar revision
- Complete the in-human Malaysian based clinical trials for the treatment of crossbite
- Gain CE marking for initial human use devices
- Develop a scaled up manufacturing process

The value of investments can go down as well as up, so you could get back less than you invested.

**For further information, please contact:**

Barbara Diehl on +44 (0) 7814 433 744 (mobile) or +44 (0) 1865 261 421 or email [barbara.diehl@oxtex.com](mailto:barbara.diehl@oxtex.com)

The information in this advertisement is believed to be correct at the date of publication, but cannot be guaranteed and is subject to change without warning. Past performance is not necessarily indicative of future performance of an investment. Forecast figures are not a reliable indicator of future performance. Some investments carry a higher degree of risk than others. Not for distribution directly or indirectly in or into the United States of America, or any jurisdiction into which the same would be unlawful. This advertisement is approved by Daniel Stewart and Company who are authorised and regulated by the Financial Conduct Authority. [www.danielstewart.co.uk](http://www.danielstewart.co.uk) © TMRM Ltd. 2011